Open an account

LENZ Therapeutics

LENZ · NASDAQ

$3.19−$0.11 (−3.33%)TodayMarket closed ·
Prev close $3.30

About LENZ

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 152 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

Employees
152
Headquarters
Solana Beach, California
Listed
Jun 25, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
lenz-tx.com

LENZ key statistics

Market cap
103.69M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
777.12K
Volume
819.24K
Open price
$3.27
High today
$3.33
Low today
$3.12
52 Week high
$39.17
52 Week low
$3.21

LENZ Therapeutics (LENZ) at a glance

LENZ Therapeutics (LENZ) last traded at $3.19, with a market cap of 103.69M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.12 and $3.33. The current price is 2.2% above the day's low and 4.2% below its high.

Volume so far is 819.24K shares, in line with the average of 777.12K shares a day.

Over the past year LENZ Therapeutics has ranged from $3.21 to $39.17, and now sits 0% of the way up that range.

LENZ Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$1.02 per share against an estimate of -$1.10.

The average analyst price target is $22.44, 603.4% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 8 analystsAvg $22.44
Low
$7.07
Now
$3.19
High
$63.00

LENZ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 13.8% on average.

  1. Q3 FY24: reported -$0.38 per share against an estimate of -$0.474
  2. Q4 FY24: reported -$0.46 per share against an estimate of -$0.4216
  3. Q1 FY25: reported -$0.53 per share against an estimate of -$0.5644
  4. Q2 FY25: reported -$0.51 per share against an estimate of -$0.6223
  5. Q3 FY25: reported -$0.59 per share against an estimate of -$0.7204
  6. Q4 FY25: reported -$1.16 per share against an estimate of -$0.9906
  7. Q1 FY26: reported -$1.32 per share against an estimate of -$1.09
  8. Q2 FY26: reported -$1.02 per share against an estimate of -$1.10

LENZ news

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Vandana Singh

    LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst

  • Press releaseGlobe Newswire

    LENZ Therapeutics, Inc. Investigated by the Portnoy Law Firm

Similar companies

Companies in the same industry as LENZ Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.